There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume

Journal of Viral Hepatitis

Volumn 18, Issue 9, 2011, Pages 637-645

  Ke, W M ^a   Xie, S B ^a   Li, X J ^a   Zhang, S Q ^a   Lai, J ^a   Ye, Y N ^a   Gao, Z L ^a   Chen, P J ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Public Health Laboratory   (United States)

Author keywords

HBeAg status; HBV DNA level; hepatic parenchyma cell volume; necroinflammation grade; pathogenesis

Indexed keywords

HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CELL VOLUME; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN;

ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; BIOPSY; CELL SIZE; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VIRUS REPLICATION; YOUNG ADULT;

EID: 79960953217     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01444.x     Document Type: Article

References (28)

1. Hadziyannis SJ, Vassilopoulos D,. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34 (4 Pt 1): 617-624. (Pubitemid 32927983)
2. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36 (2): 263-270. (Pubitemid 34146434)
3. Chan HL, Leung NW, Hussian M, et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31 (3): 763-768. (Pubitemid 30118648)
4. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33 (3): 430-439. (Pubitemid 30663381)
5. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68 (12): 8102-8110.
6. Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-munus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88 (10): 4186-4190. (Pubitemid 21914504)
7. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123 (3): 719-727. (Pubitemid 34977078)
8. Ke WM, Xie SB, Yu LN, et al. Decline of serum HBV DNA and no change apportioned by same hepatic parenchyma cell volume from hepatic fibrosis stage 1 to stage 4 during the natural history of chronic hepatitis B. Intervirology 2008; 51 (4): 235-240.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19 (6): 1513-1520. (Pubitemid 24166476)
10. Xie SB, Yao JL, Zheng SS, Yao CL, Zheng RQ,. The levels of serum fibrosis marks and morphometric quantitative measurement of hepatic fibrosis. Hepatobiliary Pancreat Dis Int 2002; 1 (2): 202-206.
11. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS, Management of hepatitis B: summary of a clinical research worship. Hepatology 2007; 45 (4): 1056-1075. (Pubitemid 46646501)
12. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45 (2): 507-539. (Pubitemid 46374607)
13. Chu CJ, Hussain M, Lok AS,. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36 (6): 1408-1415. (Pubitemid 35407438)
14. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97 (4): 265-272.
15. Yang HI, Lu SN, Liaw YF, et al. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347 (3): 168-174.
16. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of Hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1): 65-73. (Pubitemid 43042691)
17. Harris RA, Chen G, Lin WY, Shen FM, London WT, Evans AA,. Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. Cancer Causes Control 2003; 14 (10): 995-1000. (Pubitemid 38091220)
18. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (3): 678-686. (Pubitemid 43374518)
19. Liaw YF, Sung JJ, Chow WC, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15): 1521-1531.
20. Lai CL, Gane E, Liaw YF, et al. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357 (25): 2576-2588. (Pubitemid 350294224)
21. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131 (6): 1743-1751. (Pubitemid 44958517)
22. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL., Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46 (6): 1695-1703.
23. Bonino F, Marcellin P, Lau GK, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56 (5): 699-705. (Pubitemid 46662938)
24. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and Hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg positive chronic hepatitis B. Hepatology 2008; 47 (2): 428-434. (Pubitemid 351280710)
25. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36 (1): 186-194. (Pubitemid 34700777)
26. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
27. Wong DK, Yuen MF, Tse E, et al. Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necroinflammation and fibrosis. J Clin Microbiol 2004; 42 (9): 3920-3924. (Pubitemid 39296103)
28. Kim TH, Kim YS, Yeom JJ, et al. Relevancy between liver injury, serum HBV-DNA, and intrahepatic HBcAg in young male chronic HBV carriers. Korean J Gastroenterol 2004; 44 (2): 84-92.